ACAD
31.43
-2.07
-6.18%
AEMD
6.01
-0.13
-2.12%
APRI
0.4
-0.07
-14.89%
ARNA
1.81
-0.1
-5.24%
ATEC
0.28
0.00
-0.99%
CNAT
2.04
-0.09
-4.23%
CRXM
0.17
+0.02
+11.96%
CYTX
2.02
+0.02
+1.00%
DXCM
77.46
-0.13
-0.17%
GNMK
8.35
-0.62
-6.91%
HALO
8.44
-0.75
-8.16%
ILMN
138.91
-7.68
-5.24%
INNV
0.23
+0.01
+2.61%
INO
9.17
-0.68
-6.90%
ISCO
2.05
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
111.79
-3.32
-2.88%
LPTN
2.18
-0.18
-7.63%
MBVX
0.553
-0.028
-4.7414%
MEIP
1.36
+0.02
+1.49%
MNOV
7
-0.11
-1.55%
MRTX
5.98
-0.48
-7.43%
MSTX
0.45
-0.007
-1.4683%
NBIX
43.28
-1.31
-2.94%
NUVA
57.93
-0.93
-1.58%
ONCS
1.63
+0.03
+1.87%
ONVO
3.35
-0.1
-2.90%
OREX
0.449
-0.049
-9.8614%
OTIC
15.58
-0.67
-4.12%
QDEL
17.09
-0.77
-4.31%
RCPT
231.96
0.00
0.00%
RGLS
5.29
-0.45
-7.84%
RMD
60.52
-3.56
-5.56%
SCIE
0.005
0.00
-5.5556%
SPHS
1.86
-0.03
-1.59%
SRNE
5.62
-0.26
-4.42%
TROV
4.55
-0.25
-5.21%
VICL
4.47
-0.13
-2.83%
VOLC
18
0.00
0.00%
ZGNX
8.09
-0.32
-3.80%
ACAD
31.43
-2.07
-6.18%
AEMD
6.01
-0.13
-2.12%
APRI
0.4
-0.07
-14.89%
ARNA
1.81
-0.1
-5.24%
ATEC
0.28
0.00
-0.99%
CNAT
2.04
-0.09
-4.23%
CRXM
0.17
+0.02
+11.96%
CYTX
2.02
+0.02
+1.00%
DXCM
77.46
-0.13
-0.17%
GNMK
8.35
-0.62
-6.91%
HALO
8.44
-0.75
-8.16%
ILMN
138.91
-7.68
-5.24%
INNV
0.23
+0.01
+2.61%
INO
9.17
-0.68
-6.90%
ISCO
2.05
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
111.79
-3.32
-2.88%
LPTN
2.18
-0.18
-7.63%
MBVX
0.553
-0.028
-4.7414%
MEIP
1.36
+0.02
+1.49%
MNOV
7
-0.11
-1.55%
MRTX
5.98
-0.48
-7.43%
MSTX
0.45
-0.007
-1.4683%
NBIX
43.28
-1.31
-2.94%
NUVA
57.93
-0.93
-1.58%
ONCS
1.63
+0.03
+1.87%
ONVO
3.35
-0.1
-2.90%
OREX
0.449
-0.049
-9.8614%
OTIC
15.58
-0.67
-4.12%
QDEL
17.09
-0.77
-4.31%
RCPT
231.96
0.00
0.00%
RGLS
5.29
-0.45
-7.84%
RMD
60.52
-3.56
-5.56%
SCIE
0.005
0.00
-5.5556%
SPHS
1.86
-0.03
-1.59%
SRNE
5.62
-0.26
-4.42%
TROV
4.55
-0.25
-5.21%
VICL
4.47
-0.13
-2.83%
VOLC
18
0.00
0.00%
ZGNX
8.09
-0.32
-3.80%
Home » Archive by Category

Syndication

Sr Manager, Product/Market – Pyxis Supply Solutions – CareFusion – San Diego, CA

May 4, 2016 – 6:29 am

Qualifications Bachelors’ Degree with 4 years of work experience in sales, consulting or marketing OR MBA/Master’s Degree with 5 years of work experience in…
From CareFusion Corporation – 04 May 2016 13:29:13 GMT
– View all San Diego jobs

Sr Manager, Product/Market – Data and Analytics, Pyxis Supply Solutions – CareFusion – San Diego, CA

May 4, 2016 – 6:29 am

Qualifications Bachelors’ Degree with 4 years of work experience in sales, consulting or marketing OR MBA/Master’s Degree with 5 years of work experience in…
From CareFusion Corporation – 04 May 2016 13:29:01 GMT
– View all San Diego jobs

Stand Up To Cancer and Genentech Join Forces through “Be the Breakthrough” Campaign

May 4, 2016 – 6:00 am

Collaborative Project Aims to Drive Progress in Cancer Research by Educating on the Importance of Individual Contributions

NEW YORK, May 4, 2016 /PRNewswire-USNewswire/ — Stand Up To Cancer (SU2C) and Genentech announced their latest collaboration “Be the Breakthrough”, a multi-faceted campaign focused on educating Americans on how they can each play a role in the fight against cancer, including screening and participating in clinical trials.

As a result of a deeper understanding of cancer, innovative new treatments, and greater awareness of prevention and screening, deaths from cancer have decreased by more than 20 percent in the last 25 years. This progress has been made possible due to the perseverance of committed scientists who have worked to achieve breakthrough discoveries, the compassionate doctors and nurses who tirelessly provide care to improve lives, and the brave patients who participate in clinical trials to bring new medicines forward. SU2C and Genentech are committed to accelerating this momentum through their collaborations.

“Stand Up To Cancer has made incredible progress in advancing cancer research, and we are proud to further our collaboration with the hope that together we can have a significant impact on all those affected by cancer,” said Troy Cox, senior vice president, BioOncology at Genentech. “By recognizing the people and teams behind the breakthroughs made in the history of cancer, we want to empower everyone to play a role in the fight until cancer is no more.”

“Be The Breakthrough” will work to raise awareness among the public about the important role regular screenings and participation in clinical trials play in fighting cancer and also celebrate the individuals who have made major contributions to the field.

“Genentech is a valued collaborator who has long supported SU2C’s distinctive model of research,” stated Stand Up To Cancer Co-founder Lisa Paulsen, president and CEO of the Entertainment Industry Foundation. “Not only has Genentech provided financial resources to conduct our translational research, but with ‘Be the Breakthrough’, we hope to markedly increase participation of patients in clinical trials which are so essential to move science forward and bring new benefits to cancer patients.”

The multi-year collaboration with Genentech will engage the public in dynamic ways in order to continue to make big strides in the national effort to defeat cancer. “Be the Breakthrough” will activate collaborators across the entire cancer research effort, from doctors and researchers, to nurses, to patients and their loved ones through a vibrant social media campaign as well as public service announcements.

In addition to “Be the Breakthrough”, Genentech is also a collaborator in Catalyst, a new program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin was also a co-founder.  SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C’s president since 2011.

For more information on Stand Up To Cancer, visit www.standup2cancer.org.

About Genentech
Founded 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Logo – http://photos.prnewswire.com/prnh/20160429/361914

 

 

SOURCE Stand Up To Cancer

A Vision for Boosting the Life Sciences in San Diego and Beyond

May 4, 2016 – 2:40 am

The life sciences industry represents a vital piece of San Diego’s innovation economy, contributing $31.8 billion each year in local economic impact—more than defense or even tourism, according…

[[Click headline to continue reading.]]

Production Supervisor, Reagent Formulation – 1st shift working Wed-Sun – Illumina, Inc. – San Diego, CA

May 3, 2016 – 10:05 pm

The Production Supervisor will directly manage formulators on this high throughput, and high rate of change, biotechnology production line. All About Us….
From Illumina, Inc. – 04 May 2016 05:05:36 GMT
– View all San Diego jobs

Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference

May 3, 2016 – 2:30 pm

SAN DIEGO, May 3, 2016 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The discussion is scheduled for Tuesday, May 10th, at 1:00 p.m. Pacific Time.

To listen to the live webcast or a replay of the discussion, please visit the Investors section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.

Orexigen Contact:

Media Contact:

McDavid Stilwell

Julie Normart

VP, Corporate Communications and Business Development

BrewLife

(858) 875-8629

(415) 946-1087

mstilwell@orexigen.com

jnormart@brewlife.com

 

SOURCE Orexigen Therapeutics, Inc.

Rigel Announces First Quarter 2016 Financial Results

May 3, 2016 – 1:05 pm

– Conference Call and Webcast Today at 5:00 PM Eastern Time –

SOUTH SAN FRANCISCO, Calif., May 3, 2016 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016.

“We look forward to our upcoming Phase 3 data as we continue with our planning for the potential commercial launch of fostamatinib in the United States,” said Raul Rodriguez, president and chief executive officer of Rigel.  “Also, we initiated the Phase 2 proof-of-concept study with fostamatinib in autoimmune hemolytic anemia (AIHA). We anticipate that the results of these studies as well as the IgA nephropathy study will be forthcoming later this year,” he added.

During the first quarter, Rigel announced that patient enrollment was completed for the two studies in the FIT Phase 3 clinical program of fostamatinib in immune thrombocytopenic purpura (ITP). The results from the first study are expected in the middle of 2016, with the results for the second study expected shortly thereafter. Rigel plans to submit a New Drug Application to the Food and Drug Administration in the first quarter of 2017, subject to the results of the program. In addition, Rigel is in the early stages of establishing its sales and marketing infrastructure for the commercial launch of fostamatinib.

For the first quarter of 2016, Rigel reported a net loss of $17.5 million, or $0.19 per share, compared to a net loss of $18.2 million, or $0.21 per share, in the first quarter of 2015.

Contract revenues from collaborations of $5.0 million in the first quarter of 2016, compared to $2.2 million in the first quarter of 2015, were comprised of the amortization of the $30.0 million upfront payment and FTE fees earned pursuant to Rigel’s collaboration and license agreement with Bristol-Myers Squibb.

Rigel reported total costs and expenses of $22.6 million in the first quarter of 2016, compared to $20.4 million in the first quarter of 2015. The increase in costs and expenses was primarily due to the increase in research and development costs related to Rigel’s clinical research programs with fostamatinib in ITP and AIHA.

As of March 31, 2016, Rigel had cash, cash equivalents and short-term investments of $103.6 million, compared to $126.3 million as of December 31, 2015. Rigel expects this amount to be sufficient to fund operations into the third quarter of 2017.

Conference Call and Webcast Today at 5:00PM Eastern Time

Rigel will hold a live conference call and webcast today at 5:00pm Eastern Time (2:00pm Pacific Time).

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 97470871.  The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com.  The webcast will be archived and available for replay for 30 days after the call via the Rigel website.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

This press release contains “forward-looking” statements relating to, among other things, timing of reporting topline data of Phase 3 clinical studies with fostamatinib in ITP; the timing of a potential New Drug Application submission to the Food and Drug Administration for fostamatinib in ITP; the management and advancement of Rigel’s other clinical programs; Rigel’s belief that fostamatinib may be an attractive alternative for patients with ITP; Rigel’s ability to successfully prepare for potential commercial launch of its product candidates; the timing, amount and sufficiency of Rigel’s cash, cash equivalents, and short-term investments; Rigel’s ability to extend the value of Rigel’s pipeline into fields that are beyond its therapeutic focus; the evaluation of fostamatinib and Rigel’s other product candidates for new treatment indications; and Rigel’s product pipeline and development programs. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “planned,” “will,” “may,” “expect,” and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the availability of resources to develop Rigel’s product candidates, Rigel’s need for additional capital in the future to sufficiently fund Rigel’s operations and research, the uncertain timing of completion of and the success of clinical trials, risks associated with and Rigel’s dependence on Rigel’s corporate partnerships, as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2015. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Contact: Ryan D. Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com

 

RIGEL PHARMACEUTICALS, INC

STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended March 31,

2016

2015

(unaudited)

Revenues:

Contract revenues from collaborations

$          5,029

$            2,178

Costs and expenses:

Research and development (see Note A)

18,173

15,702

General and administrative (see Note A)

4,423

4,717

     Total costs and expenses

22,596

20,419

Loss from operations

(17,567)

(18,241)

Interest income

103

48

Net loss

$       (17,464)

$         (18,193)

Net loss per share, basic and diluted

$           (0.19)

$             (0.21)

Weighted-average shares used in computing net loss per share, basic and diluted

90,555

88,043

Note A

Stock-based compensation expense included in:

Research and development

$             693

$            1,160

General and administrative

745

894

$          1,438

$            2,054

SUMMARY BALANCE SHEET DATA

(in thousands)

March 31,

December 31,

2016

2015 (1)

 (unaudited)

Cash, cash equivalents and short-term investments

$      103,632

$        126,276

Total assets

108,280

131,747

Stockholders’ equity

75,452

91,381

(1)

Derived from audited financial statements

Logo – http://photos.prnewswire.com/prnh/20030226/RIGLLOGO

 

SOURCE Rigel Pharmaceuticals, Inc.

Rigel Announces First Quarter 2016 Financial Results

May 3, 2016 – 1:05 pm

– Conference Call and Webcast Today at 5:00 PM Eastern Time –

SOUTH SAN FRANCISCO, Calif., May 3, 2016 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016.

“We look forward to our upcoming Phase 3 data as we continue with our planning for the potential commercial launch of fostamatinib in the United States,” said Raul Rodriguez, president and chief executive officer of Rigel.  “Also, we initiated the Phase 2 proof-of-concept study with fostamatinib in autoimmune hemolytic anemia (AIHA). We anticipate that the results of these studies as well as the IgA nephropathy study will be forthcoming later this year,” he added.

During the first quarter, Rigel announced that patient enrollment was completed for the two studies in the FIT Phase 3 clinical program of fostamatinib in immune thrombocytopenic purpura (ITP). The results from the first study are expected in the middle of 2016, with the results for the second study expected shortly thereafter. Rigel plans to submit a New Drug Application to the Food and Drug Administration in the first quarter of 2017, subject to the results of the program. In addition, Rigel is in the early stages of establishing its sales and marketing infrastructure for the commercial launch of fostamatinib.

For the first quarter of 2016, Rigel reported a net loss of $17.5 million, or $0.19 per share, compared to a net loss of $18.2 million, or $0.21 per share, in the first quarter of 2015.

Contract revenues from collaborations of $5.0 million in the first quarter of 2016, compared to $2.2 million in the first quarter of 2015, were comprised of the amortization of the $30.0 million upfront payment and FTE fees earned pursuant to Rigel’s collaboration and license agreement with Bristol-Myers Squibb.

Rigel reported total costs and expenses of $22.6 million in the first quarter of 2016, compared to $20.4 million in the first quarter of 2015. The increase in costs and expenses was primarily due to the increase in research and development costs related to Rigel’s clinical research programs with fostamatinib in ITP and AIHA.

As of March 31, 2016, Rigel had cash, cash equivalents and short-term investments of $103.6 million, compared to $126.3 million as of December 31, 2015. Rigel expects this amount to be sufficient to fund operations into the third quarter of 2017.

Conference Call and Webcast Today at 5:00PM Eastern Time

Rigel will hold a live conference call and webcast today at 5:00pm Eastern Time (2:00pm Pacific Time).

Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-2939 (international) and using the Conference ID number 97470871.  The conference call will also be webcast live and can be accessed from Rigel’s website at www.rigel.com.  The webcast will be archived and available for replay for 30 days after the call via the Rigel website.

About Rigel (www.rigel.com)

Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo.

This press release contains “forward-looking” statements relating to, among other things, timing of reporting topline data of Phase 3 clinical studies with fostamatinib in ITP; the timing of a potential New Drug Application submission to the Food and Drug Administration for fostamatinib in ITP; the management and advancement of Rigel’s other clinical programs; Rigel’s belief that fostamatinib may be an attractive alternative for patients with ITP; Rigel’s ability to successfully prepare for potential commercial launch of its product candidates; the timing, amount and sufficiency of Rigel’s cash, cash equivalents, and short-term investments; Rigel’s ability to extend the value of Rigel’s pipeline into fields that are beyond its therapeutic focus; the evaluation of fostamatinib and Rigel’s other product candidates for new treatment indications; and Rigel’s product pipeline and development programs. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “planned,” “will,” “may,” “expect,” and similar expressions are intended to identify these forward-looking statements.  These forward-looking statements are based on Rigel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, the availability of resources to develop Rigel’s product candidates, Rigel’s need for additional capital in the future to sufficiently fund Rigel’s operations and research, the uncertain timing of completion of and the success of clinical trials, risks associated with and Rigel’s dependence on Rigel’s corporate partnerships, as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2015. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Contact: Ryan D. Maynard
Phone: 650.624.1284
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com

 

RIGEL PHARMACEUTICALS, INC

STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended March 31,

2016

2015

(unaudited)

Revenues:

Contract revenues from collaborations

$          5,029

$            2,178

Costs and expenses:

Research and development (see Note A)

18,173

15,702

General and administrative (see Note A)

4,423

4,717

     Total costs and expenses

22,596

20,419

Loss from operations

(17,567)

(18,241)

Interest income

103

48

Net loss

$       (17,464)

$         (18,193)

Net loss per share, basic and diluted

$           (0.19)

$             (0.21)

Weighted-average shares used in computing net loss per share, basic and diluted

90,555

88,043

Note A

Stock-based compensation expense included in:

Research and development

$             693

$            1,160

General and administrative

745

894

$          1,438

$            2,054

SUMMARY BALANCE SHEET DATA

(in thousands)

March 31,

December 31,

2016

2015 (1)

 (unaudited)

Cash, cash equivalents and short-term investments

$      103,632

$        126,276

Total assets

108,280

131,747

Stockholders’ equity

75,452

91,381

(1)

Derived from audited financial statements

Logo – http://photos.prnewswire.com/prnh/20030226/RIGLLOGO

 

SOURCE Rigel Pharmaceuticals, Inc.

Record Attendance Expected at Association of Bioscience Financial Officers (ABFO) 2016 National Conference

May 3, 2016 – 1:05 pm

– Biotechnology Industry Financial Leaders to Convene in San Diego, CA on May 24-27 –

SAN DIEGO, May 3, 2016 /PRNewswire/ — The Association of Bioscience Financial Officers (ABFO) today reported that record attendance is expected at the organization’s national conference, which will take place May 24-27 in San Diego, CA. 

With its central theme “Financial Leaders in Bioscience, Innovation.  Integrity.  Influence.”, the Conference is seeing pre-registration numbers close in on 200, driven by the strong interest in a broad range of keynote and guest speakers, and breakout sessions.  This year’s conference has registrations from every major biotechnology geographic “hub” in the United States, extending into Canada.  Topics and seminars will include a negotiation master class, public speaking, bridging the gap between financial and science leaders in business and how we think about innovation, communication and risk. In addition, expert panelists will discuss trends in mergers and acquisitions, a CEO’s view of managing and interacting with Boards of Directors, and more. Featured speakers and sessions include:

  • Shankar Vedantam, NPR’s social science correspondent, author and the host of the Hidden Brain podcast
  • Jim Thomas, a Washington attorney, author, speaker, trainer and one of the most acclaimed and respected negotiators in the United States
  • Joe Quinlan, Managing Director, Chief Market Strategist at Bank of America
  • Darren Snellgrove, Vice President of Finance and Chief Financial Officer of Johnson & Johnson Innovation and Johnson & Johnson Development Corporation
  • Andrew Fastow, former Chief Financial Officer at Enron
  • A motivating and inspiring glimpse into patient’s perspective on surviving cancer, and emphasis on the importance of innovation in drug discovery, hosted by the Susan G. Komen San Diego Foundation

ABFO National Conference 2016 Topics – Highlights

The following sessions are a preview of content for the upcoming 2016 ABFO National Conference. Please check the conference agenda on the website periodically for updates.

Guest Speaker: Joe Quinlan, Managing Director & Chief Market Strategist, U.S. Trust, Bank of America, Private Wealth Management

Mr. Quinlan’s talk will cover the main drivers of long-term change as key to investment success in the 21st century. We are at the beginning of a secular growth phase for the U.S. economy driven largely by the rebalancing of global growth from the developed to the developing world. Joe will discuss the long-term drivers, the macro forces and investment themes at play across industries that are taking us into the next growth cycle.

Panel Discussion:  A CEO’s View of Managing and Interacting with Your Board of Directors and Audit Committee 

This panel will bring together a seasoned group of industry veterans to discuss the current life sciences challenges presented and the opportunities and the role of the CFO in supporting the company and Board of Directors. Also, CEOs will discuss their perspectives on the role of finance in an organization and how the CFO can go from being a number cruncher to a trusted advisor to the CEO and Board.

Panel Discussion: Washington Update

This panel will provide an inside look at the issues facing the life science industry and how legislators in Washington DC and state capitals have an influence over how management runs companies. The Jobs Act, and Affordable Care Act are just two examples of major pieces of legislation that were influenced by our panel members and impacted the industry.  The IPO window many companies took advantage of was propelled by the initiatives in the Jobs Act.  The $5 billion R&D grants from the Affordable Care Act provided life science companies a needed shot in the arm as we struggled to raise capital in the depths of the recession and was the only portion of the bill where Washington actually paid out funding to assist an industry. SEC reporting, IRS tax rules, and the FDA approval process are all in the hands of our legislators and are on the forefront of advocacy issues our panel will discuss. 

“We are pleased that the ABFO Conference continues to provide a venue for financial officers to come together to discuss the state of the industry,” commented, Vanessa Jacoby, Vice President, Finance at PharmAkea Therapeutics and co-chair of the 2016 National Conference. “The national participation of speakers and attendees provides a unique perspective of this innovative industry.”

Dan Chevallard, Vice President, Finance and Accounting at Regulus Therapeutics and co-chair of the conference, said, “In addition to learning from industry leaders, participants can earn over 17 CPE credits and network with peers. The conference provides participants an unmatched opportunity to advance their leadership, expand their network and fundamentally improve their contribution as leaders in their organization.”

Registration can be completed online at: http://www.abfointernational.org/WP/abfo-national-conference/ through May 22, 2016.  The cost to attend the conference is $1,400, and over 17 hours of continuing education credits are available.  For general information about the conference, and questions about registration and billing, please contact Genie Hawkins at abfogenie@comcast.net.  

The 2016 ABFO National Conference is sponsored by Aon, Bank of America Merrill Lynch, Ernst & Young, Hughes Marino, Latham & Watkins, Medidata, Merrill Corporation, Oxford Finance and R&D Logic. The conference is also supported by Russo Partners.

About ABFO

Formed in 1989, the Association of Bioscience Financial Officers has chapters nationwide that serve as forums for the exchange of information about the industry and networking. Regional chapters are based in top bioscience hubs to allow for face-to-face meetings and discussion of hot topics of interest to bioscience financial officers. The regional chapters meet annually at the ABFO National Conference for extended networking. For more information, visit http://www.abfointernational.org

Media Contacts:

David Schull
Russo Partners LLC
Tel: (858) 717-2310
Email: david.schull@russopartnersllc.com

Alex Fudukidis  
Russo Partners LLC
Tel: (646) 942-5632
Email: alex.fudukidis@russopartnersllc.com

SOURCE Association of Bioscience Financial Officers

Record Attendance Expected at Association of Bioscience Financial Officers (ABFO) 2016 National Conference

May 3, 2016 – 1:05 pm

– Biotechnology Industry Financial Leaders to Convene in San Diego, CA on May 24-27 –

SAN DIEGO, May 3, 2016 /PRNewswire/ — The Association of Bioscience Financial Officers (ABFO) today reported that record attendance is expected at the organization’s national conference, which will take place May 24-27 in San Diego, CA. 

With its central theme “Financial Leaders in Bioscience, Innovation.  Integrity.  Influence.”, the Conference is seeing pre-registration numbers close in on 200, driven by the strong interest in a broad range of keynote and guest speakers, and breakout sessions.  This year’s conference has registrations from every major biotechnology geographic “hub” in the United States, extending into Canada.  Topics and seminars will include a negotiation master class, public speaking, bridging the gap between financial and science leaders in business and how we think about innovation, communication and risk. In addition, expert panelists will discuss trends in mergers and acquisitions, a CEO’s view of managing and interacting with Boards of Directors, and more. Featured speakers and sessions include:

  • Shankar Vedantam, NPR’s social science correspondent, author and the host of the Hidden Brain podcast
  • Jim Thomas, a Washington attorney, author, speaker, trainer and one of the most acclaimed and respected negotiators in the United States
  • Joe Quinlan, Managing Director, Chief Market Strategist at Bank of America
  • Darren Snellgrove, Vice President of Finance and Chief Financial Officer of Johnson & Johnson Innovation and Johnson & Johnson Development Corporation
  • Andrew Fastow, former Chief Financial Officer at Enron
  • A motivating and inspiring glimpse into patient’s perspective on surviving cancer, and emphasis on the importance of innovation in drug discovery, hosted by the Susan G. Komen San Diego Foundation

ABFO National Conference 2016 Topics – Highlights

The following sessions are a preview of content for the upcoming 2016 ABFO National Conference. Please check the conference agenda on the website periodically for updates.

Guest Speaker: Joe Quinlan, Managing Director & Chief Market Strategist, U.S. Trust, Bank of America, Private Wealth Management

Mr. Quinlan’s talk will cover the main drivers of long-term change as key to investment success in the 21st century. We are at the beginning of a secular growth phase for the U.S. economy driven largely by the rebalancing of global growth from the developed to the developing world. Joe will discuss the long-term drivers, the macro forces and investment themes at play across industries that are taking us into the next growth cycle.

Panel Discussion:  A CEO’s View of Managing and Interacting with Your Board of Directors and Audit Committee 

This panel will bring together a seasoned group of industry veterans to discuss the current life sciences challenges presented and the opportunities and the role of the CFO in supporting the company and Board of Directors. Also, CEOs will discuss their perspectives on the role of finance in an organization and how the CFO can go from being a number cruncher to a trusted advisor to the CEO and Board.

Panel Discussion: Washington Update

This panel will provide an inside look at the issues facing the life science industry and how legislators in Washington DC and state capitals have an influence over how management runs companies. The Jobs Act, and Affordable Care Act are just two examples of major pieces of legislation that were influenced by our panel members and impacted the industry.  The IPO window many companies took advantage of was propelled by the initiatives in the Jobs Act.  The $5 billion R&D grants from the Affordable Care Act provided life science companies a needed shot in the arm as we struggled to raise capital in the depths of the recession and was the only portion of the bill where Washington actually paid out funding to assist an industry. SEC reporting, IRS tax rules, and the FDA approval process are all in the hands of our legislators and are on the forefront of advocacy issues our panel will discuss. 

“We are pleased that the ABFO Conference continues to provide a venue for financial officers to come together to discuss the state of the industry,” commented, Vanessa Jacoby, Vice President, Finance at PharmAkea Therapeutics and co-chair of the 2016 National Conference. “The national participation of speakers and attendees provides a unique perspective of this innovative industry.”

Dan Chevallard, Vice President, Finance and Accounting at Regulus Therapeutics and co-chair of the conference, said, “In addition to learning from industry leaders, participants can earn over 17 CPE credits and network with peers. The conference provides participants an unmatched opportunity to advance their leadership, expand their network and fundamentally improve their contribution as leaders in their organization.”

Registration can be completed online at: http://www.abfointernational.org/WP/abfo-national-conference/ through May 22, 2016.  The cost to attend the conference is $1,400, and over 17 hours of continuing education credits are available.  For general information about the conference, and questions about registration and billing, please contact Genie Hawkins at abfogenie@comcast.net.  

The 2016 ABFO National Conference is sponsored by Aon, Bank of America Merrill Lynch, Ernst & Young, Hughes Marino, Latham & Watkins, Medidata, Merrill Corporation, Oxford Finance and R&D Logic. The conference is also supported by Russo Partners.

About ABFO

Formed in 1989, the Association of Bioscience Financial Officers has chapters nationwide that serve as forums for the exchange of information about the industry and networking. Regional chapters are based in top bioscience hubs to allow for face-to-face meetings and discussion of hot topics of interest to bioscience financial officers. The regional chapters meet annually at the ABFO National Conference for extended networking. For more information, visit http://www.abfointernational.org

Media Contacts:

David Schull
Russo Partners LLC
Tel: (858) 717-2310
Email: david.schull@russopartnersllc.com

Alex Fudukidis  
Russo Partners LLC
Tel: (646) 942-5632
Email: alex.fudukidis@russopartnersllc.com

SOURCE Association of Bioscience Financial Officers